Trial Profile

A pharmacokinetic and bioequivalence study of adalimumab biosimilar (CHS-1420)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications Psoriasis; Rheumatoid arthritis
Focus Pharmacokinetics; Registrational

Most Recent Events

20 Dec 2021 According to a Coherus Biosciences media release, the United States Food and Drug Administration (FDA) approved YUSIMRY (adalimumab-aqvh), formerly CHS-1420, a Humira (adalimumab) biosimilar product. Approval was based on a comprehensive data package that demonstrated the biosimilarity of YUSIMRY to the reference product, Humira. Data included results from Study CHS-1420-02 and CHS-1420-03
28 Aug 2017 Results published in a Coherus Biosciences Media Release.
02 Mar 2017 Results published in a Coherus Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com